3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
3
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
7
Leukemia, Myeloid, Acute
6
Breast Neoplasms
6
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Skin Neoplasms
3
Mesothelioma, Malignant
3
Lymphoma, Non-Hodgkin
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Sarcoma
2
Recurrence
2
Rectal Neoplasms
2
Pleural Effusion, Malignant
2
Neuroblastoma
2
Neoplasms
2
Multiple Myeloma
2
Lung Neoplasms
2
Leukemia, Myeloid
2
Leukemia
2
Head and Neck Neoplasms
2
Glioblastoma
2
Esophageal Neoplasms
2
Carcinoma, Merkel Cell
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Interventions
Carboplatin
18
Paclitaxel
17
Bevacizumab
17
olaparib
8
Specimen Handling
7
liposomal doxorubicin
6
pembrolizumab
5
Taxes
5
Biopsy
5
cemiplimab
4
Magnetic Resonance Spectroscopy
4
sarilumab
3
niraparib
3
mirvetuximab soravtansine
3
Topotecan
3
Standard of Care
3
Letrozole
3
Gemcitabine
3
Cisplatin
3
130-nm albumin-bound paclitaxel
3
taxane
2
talazoparib
2
palbociclib
2
abemaciclib
2
Temozolomide
2
Surgical Procedures, Operative
2
Practice Guidelines as Topic
2
Poly(ADP-ribose) Polymerase Inhibitors
2
Palliative Care
2
Immunoglobulin G
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Fallopian Tube Neoplasms
×
Interleukin-2
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled